Article
Oncology
Nivedita M. M. Ratnam, Heather M. M. Sonnemann, Stephen C. C. Frederico, Huanwen Chen, Marsha-Kay N. D. Hutchinson, Tyrone Dowdy, Caitlin M. M. Reid, Jinkyu Jung, Wei Zhang, Hua Song, Meili Zhang, Dionne Davis, Mioara Larion, Amber J. J. Giles, Mark R. R. Gilbert
Summary: Glioblastoma is an aggressive brain malignancy with a poor prognosis, and the limited success of immunotherapy in treating it is mainly due to inadequate tumor infiltrating lymphocytes (TILs) and restricted systemic T cell trafficking into the central nervous system (CNS).
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Bouthaina Dabaja, Michael Spiotto
Summary: Over the past half-century, the role of radiotherapy has shifted from directly killing cancer cells to stimulating anti-tumor immune responses. This interplay between radiation, the tumor microenvironment, and the immune system is crucial in cancer immunology. While most studies have focused on solid tumors, there is growing understanding of this interaction in hematological malignancies. This review highlights recent advances in immunotherapy and adoptive cell therapy and emphasizes the importance of incorporating radiation therapy into the treatment of hematological malignancies.
FRONTIERS IN ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Kaili Deng, Dongxue Yang, Yuping Zhou
Summary: Immune evasion is a common cause of failure in anticancer immune therapy. Nanotechnology-based siRNA delivery strategies have shown great potential for overcoming immune evasion by activating immune responses and delivering immunomodulatory agents to the tumor microenvironment. This review discusses the current advances and challenges in using nanotechnology for siRNA delivery and offers insights into therapeutic options for clinical cancer treatment.
Review
Immunology
Ayda Baghery Saghchy Khorasani, Amir-Mohammad Yousefi, Davood Bashash
Summary: CAR NK cells have attracted attention as a viable alternative to CAR T cells due to their MHC-independency, shorter life expectancy, potential for off-the-shelf immune product creation, and potent antitumor properties. This article provides an updated review of the differences between CAR T and CAR NK cells, current enhancements in CAR NK design, sources for collecting NK cells, and strategies for transducing CARs to NK cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Mick J. M. van Eijs, Lotte E. van der Wagen, Rogier Mous, Roos J. Leguit, Lisette van de Corput, Anne S. R. van Lindert, Britt B. M. Suelmann, Anna M. Kamphuis, Stefan Nierkens, Karijn P. M. Suijkerbuijk
Summary: Immune checkpoint inhibition (ICI) has shown promise in treating advanced malignancies, but there have been reported cases of hematological neoplasia following ICI for solid tumors. In this study, we present five cases of myeloid malignancies (chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, chronic eosinophilic leukemia) in patients treated with anti-PD-1-based therapy. Molecular analyses were performed to identify baseline variants in myeloid genes, and we discuss the potential mechanisms underlying the progression to myeloid malignancies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Oncology
Kartika Venugopal, Yang Feng, Daniil Shabashvili, Olga A. Guryanova
Summary: DNMT3A is one of the most frequently mutated genes in hematologic malignancies and plays a crucial role in epigenetic regulation. Mutations in DNMT3A have significant effects on DNA methylation and gene expression, contributing to the pathogenesis of hematologic malignancies.
Review
Oncology
Jia Xu, Wenjing Luo, Chenggong Li, Heng Mei
Summary: CD19-targeted CAR-T cell therapy has shown remarkable efficacy in treating B-cell malignancies, but CD19-negative relapse remains a significant challenge. CD22 serves as a potential alternative target for CD19 CAR-T cell-resistant patients, with therapies showing acceptable toxicities and promising efficacy.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2023)
Review
Oncology
Yuqing Wang, Ruihao Huang, Zheng Wang, Jingkang Xiong, Xiaoqi Wang, Xi Zhang
Summary: Since the implementation of allo-HSCT, many patients with hematologic malignancies have achieved a favorable overall survival rate. However, GVHD and complications of immunosuppressive drugs remain major causes of non-relapse mortality and poor quality of life. Moreover, GVHD and toxicity still occur with DLIs and CAR T-cell therapy. Universal immune cell therapy, with its immune tolerance characteristics and anti-tumor ability, has the potential to reduce GVHD and tumor burden. However, its widespread application is hindered by expansion and persistence efficacy issues. Various strategies, such as universal cell lines, signaling regulation, and CAR technology, have been explored to address this challenge. This review summarizes current advances and future perspectives in universal immune cell therapy for hematologic malignancies.
CANCER BIOLOGY & MEDICINE
(2023)
Review
Oncology
Saeed Khalili, Fatemeh Zeinali, Atousa Moghadam Fard, Seyed Reza Taha, Andarz Fazlollahpour Naghibi, Kimia Bagheri, Mahdieh Shariat Zadeh, Yeghaneh Eslami, Khashayar Fattah, Naghmeh Asadimanesh, Armin Azarimatin, Bahman Khalesi, Faezeh Almasi, Zahra Payandeh
Summary: Tumor-associated macrophages (TAMs) are immunosuppressive myeloid cells that play significant roles in tumor progression. The M1 and M2-polarized phenotypes of TAMs have been implicated in various cancers and autoimmune diseases. Understanding the precise function of TAMs is important for cancer treatment strategies.
Article
Chemistry, Multidisciplinary
M. Tommy Gambles, Jiyuan Yang, Jindrich Kopecek
Summary: The concept of multi-targeted immunotherapeutic systems has revolutionized cancer immunotherapy by engaging the patient's immune system in various ways. The outcomes range from recruiting and activating immune cells upon recognizing cancer cells, to implementing a multi-pronged immune checkpoint blockade strategy, or achieving direct cancer cell death through engaging multiple cell surface receptors. This review focuses on the application of multi-specific immunotherapeutics for B cell malignancies, outlining diverse strategies, summarizing B cell receptor antigen targeting approaches, and discussing the challenges and future prospects of the field.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Multidisciplinary Sciences
Yongxian Hu, Jingjing Li, Fang Ni, Zhongli Yang, Xiaohua Gui, Zhiwei Bao, Houli Zhao, Guoqing Wei, Yiyun Wang, Mingming Zhang, Ruimin Hong, Linqin Wang, Wenjun Wu, Mohamad Mohty, Arnon Nagler, Alex H. Chang, Marcel R. M. van den Brink, Ming D. Li, He Huang
Summary: This study compares the gut microbiome diversity and composition during different phases of CAR-T therapy and finds that it is associated with patient response to therapy and occurrence of immune-related adverse effects.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Hannah Wurzer, Liza Filali, Celine Hoffmann, Max Krecke, Andrea Michela Biolato, Jerome Mastio, Sigrid De Wilde, Jean Hugues Francois, Anne Largeot, Guy Berchem, Jerome Paggetti, Etienne Moussay, Clement Thomas
Summary: The study found that CLL cells can undergo rapid actin cytoskeleton remodeling during NK cell attack, leading to resistance against cytotoxicity. Pharmacological targeting of CLL cell actin cytoskeleton can increase granzyme B levels and restore sensitivity to NK cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Claudia Maria Hattinger, Iris Chiara Salaroglio, Leonardo Fantoni, Martina Godel, Chiara Casotti, Joanna Kopecka, Katia Scotlandi, Toni Ibrahim, Chiara Riganti, Massimo Serra
Summary: In order to improve the prognosis and cure rate of high-grade osteosarcomas (HGOSs), immune-based treatment approaches, especially for metastatic, relapsed and refractory HGOS patients, have been considered. This review provides an overview of immunotherapeutic treatments targeting, counteracting or exploiting the different immune cell compartments present in the HGOS tumor microenvironment. The strategies and possible mechanisms of HGOS cells to escape these treatments are discussed, as well as ongoing immune-based trials and recent clinical study results.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Sofia Miron-Barroso, Elena B. Domenech, Sonia Trigueros
Summary: Nanomaterials are being developed for gene delivery, but challenges such as low efficiency and potential toxicity need to be addressed. Advancements in nanotechnology are crucial for overcoming these limitations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Multidisciplinary
Ningning Niu, Xuqing Shen, Li Zhang, Yueyue Chen, Ping Lu, Wenjuan Yang, Mingzhu Liu, Juanjuan Shi, Dapeng Xu, Yingying Tang, Xiaotong Yang, Yawen Weng, Xinxin Zhao, Lian-Ming Wu, Yongwei Sun, Jing Xue
Summary: This study reveals how Setd2 deficiency in pancreatic cancer reprograms neutrophils to an immunosuppressive phenotype, promoting immune escape. Mechanistically, Setd2 deficiency leads to the gain of H3K27me3, which downregulates CXADR expression, activating the PI3K-AKT pathway and excessive expression of CXCL1 and GM-CSF, thereby promoting neutrophil recruitment and reprogramming.